Zoetis Inc. (ZTS) FCF Payout Ratio: 42.77%
Is Zoetis Inc.’s FCF payout ratio high or low?
Zoetis Inc.'s FCF payout ratio of 42.77% is 21% above its 5-year average of 35.32%, near the high end of its 5-year range (22.71%–46.08%).
The FCF payout ratio for Zoetis Inc. (ZTS) is 42.77%. It is above its 12-month average by 16.95% (36.57%).
ZTS FCF Payout Ratio Chart
ZTS Average FCF Payout Ratio Chart
ZTS Current vs Average FCF Payout Ratio Chart
ZTS FCF Payout Ratio Metrics
FCF PAYOUT RATIO
42.77%
FCF PAYOUT RATIO AVG TTM
36.57%
FCF PAYOUT RATIO AVG 3Y
40.48%
FCF PAYOUT RATIO AVG 5Y
35.32%
FCF PAYOUT RATIO AVG 10Y
31.50%
FCF PAYOUT RATIO AVG 15Y
43.34%
FCF PAYOUT RATIO AVG 20Y
43.34%
CURRENT VS TTM AVG
+16.95%
CURRENT VS 3Y AVG
+5.66%
CURRENT VS 5Y AVG
+21.09%
CURRENT VS 10Y AVG
+35.76%
CURRENT VS 15Y AVG
-1.32%
CURRENT VS 20Y AVG
-1.32%
Payout Ratio Comparison
FCF Payout Ratio
42.8%
Earnings Payout Ratio
34.2%
Dividend Yield
2.51%
FCF Yield
6.15%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $2.28B | $889.00M | 38.9% |
| 2024 | $2.30B | $786.00M | 34.2% |
| 2023 | $1.62B | $692.00M | 42.7% |
| 2022 | $1.33B | $611.00M | 46.1% |
| 2021 | $1.74B | $474.00M | 27.3% |
| 2020 | $1.67B | $380.00M | 22.7% |
| 2019 | $1.33B | $314.00M | 23.5% |
| 2018 | $1.45B | $243.00M | 16.7% |
| 2017 | $1.12B | $206.00M | 18.4% |
| 2016 | $497.00M | $188.00M | 37.8% |
| 2015 | $440.00M | $168.00M | 38.2% |
| 2014 | $431.00M | $146.00M | 33.9% |
| 2013 | $497.00M | $98.00M | 19.7% |
| 2012 | $328.00M | $63.00M | 19.2% |
| 2011 | $362.00M | $416.00M | 114.9% |
| 2010 | $130.00M | $207.00M | 159.2% |
| 2009 | ($37.00M) | $101.00M | N/A (Loss) |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Zoetis Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Zoetis Inc. (ZTS)?
- The FCF payout ratio for ZTS stock is 42.77%.
- Is Zoetis Inc.'s FCF payout ratio high or low?
- Zoetis Inc.'s FCF payout ratio of 42.77% is 21% above its 5-year average of 35.32%, near the high end of its 5-year range (22.71%–46.08%).
- What is the TTM average FCF payout ratio for Zoetis Inc. (ZTS)?
- The TTM average FCF payout ratio for ZTS stock is 36.57%.
- What is the 3Y average FCF payout ratio for Zoetis Inc. (ZTS)?
- The 3Y average FCF payout ratio for ZTS stock is 40.48%.
- What is the 5Y average FCF payout ratio for Zoetis Inc. (ZTS)?
- The 5Y average FCF payout ratio for ZTS stock is 35.32%.
- What is the 10Y average FCF payout ratio for Zoetis Inc. (ZTS)?
- The 10Y average FCF payout ratio for ZTS stock is 31.50%.
- What is the 15Y average FCF payout ratio for Zoetis Inc. (ZTS)?
- The 15Y average FCF payout ratio for ZTS stock is 43.34%.
- What is the 20Y average FCF payout ratio for Zoetis Inc. (ZTS)?
- The 20Y average FCF payout ratio for ZTS stock is 43.34%.
Zoetis Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 38.94% |
| 2024-12-31 | 34.20% |
| 2023-12-31 | 42.69% |
| 2022-12-31 | 46.08% |
| 2021-12-31 | 27.30% |
| 2020-12-31 | 22.71% |
| 2019-12-31 | 23.52% |
| 2018-12-31 | 16.74% |
| 2017-12-31 | 18.36% |
| 2016-12-31 | 37.83% |
| 2015-12-31 | 38.18% |
| 2014-12-31 | 33.87% |
| 2013-12-31 | 19.72% |
| 2012-12-31 | 19.21% |
| 2011-12-31 | 114.92% |
| 2010-12-31 | 159.23% |
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck